Skip to Content



(brin ZOH la mide)

Dosage Forms

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Suspension, Ophthalmic:

Azopt: 1% (10 mL, 15 mL)

Brand Names: U.S.

  • Azopt

Pharmacologic Category

  • Carbonic Anhydrase Inhibitor (Ophthalmic)
  • Ophthalmic Agent, Antiglaucoma


Brinzolamide inhibits carbonic anhydrase, leading to decreased aqueous humor secretion. This results in a reduction of intraocular pressure.


Topical: Into systemic circulation


Accumulates in red blood cells, binding to carbonic anhydrase (brinzolamide and metabolite)


To N-desethyl brinzolamide


Urine (as unchanged drug and metabolites)

Protein Binding


Use: Labeled Indications

Treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma


Hypersensitivity to brinzolamide or any component of the formulation


Ophthalmic: Adults: Ocular hypertension or open-angle glaucoma: Instill 1 drop in affected eye(s) 3 times/day

Dosage adjustment in renal impairment: Severe renal impairment (CrCl <30 mL/minute): Use is not recommended (has not been studied; brinzolamide and metabolite are excreted predominately by the kidney).

Dosage adjustment in hepatic impairment: No dosage adjustment provided in manufacturer’s labeling.


Remove contact lenses prior to administration; wait 15 minutes before reinserting. If more than one topical ophthalmic drug is being used, administer drugs at least 10 minutes apart. Shake well before use.


Store at 4°C to 30°C (39°F to 86°F). Shake well before use.

Drug Interactions

Alpha-/Beta-Agonists (Indirect-Acting): Carbonic Anhydrase Inhibitors may increase the serum concentration of Alpha-/Beta-Agonists (Indirect-Acting). Monitor therapy

Carbonic Anhydrase Inhibitors: May enhance the adverse/toxic effect of other Carbonic Anhydrase Inhibitors. The development of acid-base disorders with concurrent use of ophthalmic and oral carbonic anhydrase inhibitors has been reported. Management: Avoid concurrent use of different carbonic anhydrase inhibitors if possible. Monitor patients closely for the occurrence of kidney stones and with regards to severity of metabolic acidosis. Avoid combination

CYP3A4 Inhibitors (Strong): May increase the serum concentration of Brinzolamide. Monitor therapy

Adverse Reactions

1% to 10%:

Cardiovascular: Hyperemia (1% to 5%)

Central nervous system: Headache (1% to 5%)

Dermatologic: Dermatitis (1% to 5%)

Gastrointestinal: Taste disturbances (5% to 10%)

Ocular: Blurred vision (5% to 10%), blepharitis (1% to 5%), dry eye (1% to 5%), eye discharge (1% to 5%), eye discomfort (1% to 5%), eye pain (1% to 5%), foreign body sensation (1% to 5%), itching of eye (1% to 5%), keratitis (1% to 5%)

Respiratory: Rhinitis (1% to 5%)

<1% (Limited to important or life-threatening): Allergic reactions, alopecia, chest pain, conjunctivitis, diarrhea, diplopia, dizziness, dyspepsia, dyspnea, eye fatigue, hypertonia, keratoconjunctivitis, keratopathy, kidney pain, lid crusting, nausea, pharyngitis, tearing, urticaria, xerostomia


Concerns related to adverse effects:

• Sulfonamide (“sulfa”) allergy: The FDA-approved product labeling for many medications containing a sulfonamide chemical group includes a broad contraindication in patients with a prior allergic reaction to sulfonamides. There is a potential for cross-reactivity between members of a specific class (eg, two antibiotic sulfonamides). However, concerns for cross-reactivity have previously extended to all compounds containing the sulfonamide structure (SO2NH2). An expanded understanding of allergic mechanisms indicates cross-reactivity between antibiotic sulfonamides and nonantibiotic sulfonamides may not occur or at the very least this potential is extremely low (Brackett 2004; Johnson 2005; Slatore 2004; Tornero 2004). In particular, mechanisms of cross-reaction due to antibody production (anaphylaxis) are unlikely to occur with nonantibiotic sulfonamides. T-cell-mediated (type IV) reactions (eg, maculopapular rash) are less well understood and it is not possible to completely exclude this potential based on current insights. In cases where prior reactions were severe (Stevens-Johnson syndrome/TEN), some clinicians choose to avoid exposure to these classes.

Disease-related concerns:

• Acute angle-closure glaucoma: Use has not been studied in acute angle-closure glaucoma.

• Corneal endothelium: Use with caution in patients with low endothelial cell counts; may be at increased risk of corneal edema.

• Renal impairment: Use is not recommended in patients with severe renal impairment (has not been studied).

Concurrent drug therapy issues:

• Oral carbonic anhydrase inhibitors: Concurrent use with oral carbonic anhydrase inhibitors may result in additive systemic effects and is not recommended.

Special populations:

• Contact lens wearers: Product contains benzalkonium chloride which may be absorbed by soft contact lenses; remove lens prior to administration and wait 15 minutes before reinserting.

Monitoring Parameters

Intraocular pressure

Pregnancy Risk Factor


Pregnancy Considerations

Adverse effects have been observed in animal reproduction studies.

Patient Education

• Discuss specific use of drug and side effects with patient as it relates to treatment. (HCAHPS: During this hospital stay, were you given any medicine that you had not taken before? Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? How often did hospital staff describe possible side effects in a way you could understand?)

• Patient may experience blurred vision, parageusia, xerophthalmia, eye discharge, headache, or rhinorrhea. Have patient report immediately to prescriber vision changes, ophthalmalgia, severe eye irritation, or signs of Stevens-Johnson syndrome/toxic epidermal necrolysis (HCAHPS).

• Educate patient about signs of a significant reaction (eg, wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat). Note: This is not a comprehensive list of all side effects. Patient should consult prescriber for additional questions.

Intended Use and Disclaimer: Should not be printed and given to patients. This information is intended to serve as a concise initial reference for healthcare professionals to use when discussing medications with a patient. You must ultimately rely on your own discretion, experience and judgment in diagnosing, treating and advising patients.